drug protocol number

GBT440-032

drug sponsor

Sponsor (Global Blood Therapeutics, Inc.)

drug study

Voxelotor (GBT440)

drug trial site

King Khalid University Hospital (Riyadh)

drug status

Ongoing

drug phase